BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 33457012)

  • 1. Highly expressed Claudin18.2 as a potential therapeutic target in advanced gastric signet-ring cell carcinoma (SRCC).
    Xu B; Liu F; Liu Q; Shi T; Wang Z; Wu N; Xu X; Li L; Fan X; Yu L; Liu B; Wei J
    J Gastrointest Oncol; 2020 Dec; 11(6):1431-1439. PubMed ID: 33457012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of frequent CLDN18-ARHGAP26/6 fusion in gastric signet-ring cell cancer.
    Shu Y; Zhang W; Hou Q; Zhao L; Zhang S; Zhou J; Song X; Zhang Y; Jiang D; Chen X; Wang P; Xia X; Liao F; Yin D; Chen X; Zhou X; Zhang D; Yin S; Yang K; Liu J; Fu L; Zhang L; Wang Y; Zhang J; An Y; Cheng H; Zheng B; Sun H; Zhao Y; Wang Y; Xie D; Ouyang L; Wang P; Zhang W; Qiu M; Fu X; Dai L; He G; Yang H; Cheng W; Yang L; Liu B; Li W; Dong B; Zhou Z; Wei Y; Peng Y; Xu H; Hu J
    Nat Commun; 2018 Jun; 9(1):2447. PubMed ID: 29961079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular profiling of signet-ring-cell carcinoma (SRCC) from the stomach and colon reveals potential new therapeutic targets.
    Puccini A; Poorman K; Catalano F; Seeber A; Goldberg RM; Salem ME; Shields AF; Berger MD; Battaglin F; Tokunaga R; Naseem M; Zhang W; Philip PA; Marshall JL; Korn WM; Lenz HJ
    Oncogene; 2022 Jun; 41(26):3455-3460. PubMed ID: 35618879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of Claudin18.2 expression with clinicopathological characteristics and prognosis in gastric cancer.
    Tao D; Guan B; Li Z; Jiao M; Zhou C; Li H
    Pathol Res Pract; 2023 Aug; 248():154699. PubMed ID: 37487317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential therapeutic targets discovery by transcriptome analysis of an in vitro human gastric signet ring carcinoma model.
    Yamaguchi K; Yoshihiro T; Ariyama H; Ito M; Nakano M; Semba Y; Nogami J; Tsuchihashi K; Yamauchi T; Ueno S; Isobe T; Shindo K; Moriyama T; Ohuchida K; Nakamura M; Nagao Y; Ikeda T; Hashizume M; Konomi H; Torisu T; Kitazono T; Kanayama T; Tomita H; Oda Y; Kusaba H; Maeda T; Akashi K; Baba E
    Gastric Cancer; 2022 Sep; 25(5):862-878. PubMed ID: 35661943
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Wu N; Huang Y; Liu F; Xu X; Liu B; Wei J
    J Gastrointest Oncol; 2021 Jun; 12(3):1020-1030. PubMed ID: 34295553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Claudin18.2 is a novel molecular biomarker for tumor-targeted immunotherapy.
    Cao W; Xing H; Li Y; Tian W; Song Y; Jiang Z; Yu J
    Biomark Res; 2022 May; 10(1):38. PubMed ID: 35642043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Claudin18.2 expression and clinicopathological features in cytology effusion specimens from gastric adenocarcinoma: A comparative study with tissue specimens.
    Dai J; Zheng H; Jin J; Cheng Y; Xu H
    Cancer Cytopathol; 2023 Jun; 131(6):365-372. PubMed ID: 36793190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intracellular MUC20 variant 2 maintains mitochondrial calcium homeostasis and enhances drug resistance in gastric cancer.
    Fu L; Yonemura A; Yasuda-Yoshihara N; Umemoto T; Zhang J; Yasuda T; Uchihara T; Akiyama T; Kitamura F; Yamashita K; Okamoto Y; Bu L; Wei F; Hu X; Liu Y; Ajani JA; Tan P; Baba H; Ishimoto T
    Gastric Cancer; 2022 May; 25(3):542-557. PubMed ID: 35166958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathological significance and immunotherapeutic outcome of claudin 18.2 expression in advanced gastric cancer: A retrospective study.
    Qi C; Chong X; Zhou T; Ma M; Gong J; Zhang M; Li J; Xiao J; Peng X; Liu Z; Li Z; Shen L; Zhang X
    Chin J Cancer Res; 2024 Feb; 36(1):78-89. PubMed ID: 38455365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Implications of Claudin18.2 Expression in Patients With Gastric Cancer.
    Baek JH; Park DJ; Kim GY; Cheon J; Kang BW; Cha HJ; Kim JG
    Anticancer Res; 2019 Dec; 39(12):6973-6979. PubMed ID: 31810969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival benefit of palliative gastrectomy followed by chemotherapy in stage IV gastric signet ring cell carcinoma patients: A large population-based study.
    Shi T; Song X; Liu Q; Yang Y; Yu L; Liu B; Wei J
    Cancer Med; 2019 Oct; 8(13):6010-6020. PubMed ID: 31448584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular genetic and clinical characteristic analysis of primary signet ring cell carcinoma of urinary bladder identified by a novel OR2L5 mutation.
    Alradhi M; Wen S; Safi M; Al-Danakh A; Wang H; Shopit A; Sun M; Fan B; Li X
    Cancer Med; 2023 Feb; 12(4):3931-3951. PubMed ID: 36779496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Claudin18.2-Specific Chimeric Antigen Receptor Engineered T Cells for the Treatment of Gastric Cancer.
    Jiang H; Shi Z; Wang P; Wang C; Yang L; Du G; Zhang H; Shi B; Jia J; Li Q; Wang H; Li Z
    J Natl Cancer Inst; 2019 Apr; 111(4):409-418. PubMed ID: 30203099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and genomic characteristics of mucosal signet-ring cell carcinoma in Helicobacter pylori-uninfected stomach.
    Kiso M; Urabe Y; Ito M; Masuda K; Boda T; Kotachi T; Hata K; Yorita N; Nagasaki N; Abduwali M; Hiyama Y; Oka S; Tanaka S; Chayama K
    BMC Gastroenterol; 2020 Jul; 20(1):243. PubMed ID: 32727394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CLDN18.2 expression and its impact on prognosis and the immune microenvironment in gastric cancer.
    Wang C; Wang Y; Chen J; Wang Y; Pang C; Liang C; Yuan L; Ma Y
    BMC Gastroenterol; 2023 Aug; 23(1):283. PubMed ID: 37582713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genomic alterations in signet ring and mucinous patterned colorectal carcinoma.
    Kim H; Kim BH; Lee D; Shin E
    Pathol Res Pract; 2019 Oct; 215(10):152566. PubMed ID: 31400926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Difference Between Signet Ring Cell Gastric Cancers and Non-Signet Ring Cell Gastric Cancers: A Systematic Review and Meta-Analysis.
    Zhang C; Liu R; Zhang WH; Chen XZ; Liu K; Yang K; Chen XL; Zhao LY; Chen ZX; Zhou ZG; Hu JK
    Front Oncol; 2021; 11():618477. PubMed ID: 34026606
    [No Abstract]   [Full Text] [Related]  

  • 19. Zolbetuximab for Claudin18.2-positive gastric or gastroesophageal junction cancer.
    Kubota Y; Shitara K
    Ther Adv Med Oncol; 2024; 16():17588359231217967. PubMed ID: 38188462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CDH1 gene mutation in early-onset, colorectal signet-ring cell carcinoma.
    Aitchison A; Hakkaart C; Whitehead M; Khan S; Siddique S; Ahmed R; Frizelle FA; Keenan JI
    Pathol Res Pract; 2020 May; 216(5):152912. PubMed ID: 32147272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.